Taken together, CD69, an early activation marker in mouse and human T cells, demonstrates robust expression at 24 hours postactivation and is not expressed in GL261 glioma cells or nonhematopoietic cells within the GL261 tumor microenvironment (TME); suggesting that it can be a suitable biomarker for immuno-PET imaging. Here, CD69 is linked to central nervous system cancer.